These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 37258054)
1. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis. Miyata K; Bainto EV; Sun X; Jain S; Dummer KB; Burns JC; Tremoulet AH Arch Dis Child; 2023 Oct; 108(10):833-838. PubMed ID: 37258054 [TBL] [Abstract][Full Text] [Related]
2. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population. Friedman KG; Gauvreau K; Hamaoka-Okamoto A; Tang A; Berry E; Tremoulet AH; Mahavadi VS; Baker A; deFerranti SD; Fulton DR; Burns JC; Newburger JW J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633390 [TBL] [Abstract][Full Text] [Related]
3. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis. Friedman KG; Gauvreau K; Baker A; Son MB; Sundel R; Dionne A; Giorgio T; De Ferranti S; Newburger JW Arch Dis Child; 2021 Mar; 106(3):247-252. PubMed ID: 32943389 [TBL] [Abstract][Full Text] [Related]
4. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis. Dionne A; Burns JC; Dahdah N; Tremoulet AH; Gauvreau K; de Ferranti SD; Baker AL; Son MB; Gould P; Fournier A; Newburger JW; Friedman KG Pediatrics; 2019 Jun; 143(6):. PubMed ID: 31048414 [TBL] [Abstract][Full Text] [Related]
5. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin. Matsuoka R; Furuno K; Nanishi E; Onoyama S; Nagata H; Yamamura K; Sugitani Y; Kuraoka A; Mizuno Y; Sagawa K; Honjo S; Hara T; Ohga S J Pediatr; 2020 Dec; 227():224-230.e3. PubMed ID: 32810506 [TBL] [Abstract][Full Text] [Related]
6. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective? Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447 [TBL] [Abstract][Full Text] [Related]
7. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol. Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139 [TBL] [Abstract][Full Text] [Related]
8. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE. Iio K; Morikawa Y; Miyata K; Kaneko T; Misawa M; Yamagishi H; Miura M J Pediatr; 2022 Jan; 240():158-163.e4. PubMed ID: 34461064 [TBL] [Abstract][Full Text] [Related]
9. Association of Severity of Coronary Artery Aneurysms in Patients With Kawasaki Disease and Risk of Later Coronary Events. Miura M; Kobayashi T; Kaneko T; Ayusawa M; Fukazawa R; Fukushima N; Fuse S; Hamaoka K; Hirono K; Kato T; Mitani Y; Sato S; Shimoyama S; Shiono J; Suda K; Suzuki H; Maeda J; Waki K; ; Kato H; Saji T; Yamagishi H; Ozeki A; Tomotsune M; Yoshida M; Akazawa Y; Aso K; Doi S; Fukasawa Y; Furuno K; Hayabuchi Y; Hayashi M; Honda T; Horita N; Ikeda K; Ishii M; Iwashima S; Kamada M; Kaneko M; Katyama H; Kawamura Y; Kitagawa A; Komori A; Kuraishi K; Masuda H; Matsuda S; Matsuzaki S; Mii S; Miyamoto T; Moritou Y; Motoki N; Nagumo K; Nakamura T; Nishihara E; Nomura Y; Ogata S; Ohashi H; Okumura K; Omori D; Sano T; Suganuma E; Takahashi T; Takatsuki S; Takeda A; Terai M; Toyono M; Watanabe K; Watanabe M; Yamamoto M; Yamamura K JAMA Pediatr; 2018 May; 172(5):e180030. PubMed ID: 29507955 [TBL] [Abstract][Full Text] [Related]
10. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms. Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995 [TBL] [Abstract][Full Text] [Related]
11. Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan. Takekoshi N; Kitano N; Takeuchi T; Suenaga T; Kakimoto N; Suzuki T; Kada TT; Shibuta S; Tachibana S; Murayama Y; Yamaga H; Suzuki H JAMA Netw Open; 2022 Jun; 5(6):e2216642. PubMed ID: 35696166 [TBL] [Abstract][Full Text] [Related]
12. Patterns of Fever in Children After Primary Treatment for Kawasaki Disease. Jaggi P; Wang W; Dvorchik I; Printz B; Berry E; Kovalchin JP; Texter K; Ramilo O; Burns JC; Tremoulet AH Pediatr Infect Dis J; 2015 Dec; 34(12):1315-8. PubMed ID: 26353031 [TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Coronary Artery Aneurysm in a Chinese Pediatric Population with Kawasaki Disease at Low Risk of Intravenous Immunoglobulin Resistance: A Retrospective Cohort Study. Liu J; Su D; Yuan P; Ye B; Qin S; Pang Y Cardiology; 2023; 148(5):457-468. PubMed ID: 37231847 [TBL] [Abstract][Full Text] [Related]
14. Effective infliximab therapy for the early regression of coronary artery aneurysm in Kawasaki disease. Nagatomo Y; Muneuchi J; Nakashima Y; Nanishi E; Shirozu H; Watanabe M; Uike K; Nagata H; Hirata Y; Yamamura K; Takahashi Y; Okada S; Suzuki Y; Hasegawa S; Ohga S Int J Cardiol; 2018 Nov; 271():317-321. PubMed ID: 30144998 [TBL] [Abstract][Full Text] [Related]
15. [Analysis of 2 diagnostic criteria of echocardiography for coronary artery aneurysm in Kawasaki disease]. Liu WQ; Xia B; Fan W; Yu Z; Lin WL; Chen L; Wang C; Liu BN; Li J; Yang J Zhonghua Er Ke Za Zhi; 2022 Jun; 60(6):588-593. PubMed ID: 35658368 [No Abstract] [Full Text] [Related]
16. Blood routine risk factors for coronary artery aneurysm in infants younger than 8 months with Kawasaki disease. Haiyan G; Jianming L; Suqian T; Dong Q; Shuang L; Jin Z BMC Pediatr; 2022 Jan; 22(1):29. PubMed ID: 34996405 [TBL] [Abstract][Full Text] [Related]
17. [Retrospective analysis of infliximab in the treatment of Kawasaki disease]. Xie LP; Zhao L; Chu C; He L; Liang XC; Sun SN; Zhao QM; Wang F; Cao YY; Lin YX; Zeng ZQ; Wu L; Huang GY; Liu F Zhonghua Er Ke Za Zhi; 2022 Jan; 60(1):14-19. PubMed ID: 34986617 [No Abstract] [Full Text] [Related]
18. Methylprednisolone pulse and prednisolone for intensification of primary treatment in Kawasaki disease patients at high risk of treatment resistance: a multicenter prospective cohort study. Miura M; Miyata K; Kaneko T; Akahoshi S; Morikawa Y; Matsushima T; Sakakibara H; Kobayashi T; Nakamura T; Takahashi T; Nakazawa M; Shibata A; Yamagishi H Eur J Pediatr; 2024 Oct; 183(10):4265-4274. PubMed ID: 39048743 [TBL] [Abstract][Full Text] [Related]
19. Predicting Coronary Artery Aneurysms in Kawasaki Disease at a North American Center: An Assessment of Baseline Son MBF; Gauvreau K; Kim S; Tang A; Dedeoglu F; Fulton DR; Lo MS; Baker AL; Sundel RP; Newburger JW J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28566299 [TBL] [Abstract][Full Text] [Related]